Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
NCT ID: NCT03846180
Last Updated: 2019-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1682 participants
OBSERVATIONAL
2019-03-01
2019-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury
NCT07252401
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
NCT00534677
Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed
NCT06815770
Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis
NCT03130127
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis
NCT06122753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Terlipressin group
Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
Terlipressin
Continuous or intermittent intravenous infusion of terlipressin was given.
Somatostatin/Octreotide group
Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
Somatostatin
Continuous or intermittent intravenous infusion of somatostatin was given.
Octreotide
Continuous or intermittent intravenous infusion of octreotide was given.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Terlipressin
Continuous or intermittent intravenous infusion of terlipressin was given.
Somatostatin
Continuous or intermittent intravenous infusion of somatostatin was given.
Octreotide
Continuous or intermittent intravenous infusion of octreotide was given.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A diagnosis of acute gastrointestinal bleeding.
3. Patients who received terlipressin or somatostatin/octreotide.
4. Age or sex was not limited.
5. Use of endoscopy was not limited.
6. Comorbidity was not limited.
7. Malignancy was not limited.
Exclusion Criteria
2. Absence of baseline serum creatinine.
3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.
4. Duration of terlipressin or somatostatin/octreotide was less 3 days.
5. Patients who underwent transjugular intrahepatic portosystemic shunt.
6. Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General Hospital of Shenyang Military Region
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xingshun Qi
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Liver Cirrhosis, The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Liver Research Center, The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Department of Hepatobiliary Disease, 900 Hospital of the Joint Logistics Team (formerly called Fuzhou General Hospital)
Fuzhou, Fujian, China
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Department of Gastroenterology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Department of Critical Care Medicine, The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China
Department of Gastroenterology, Air Force Hospital of Northern Theater Command
Shenyang, Liaoning, China
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China
Department of Gastroenterology, Xi'an Central Hospital
Xi'an, Shaanxi, China
Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University
Jinan, Shandong, China
Eastern Hepatobiliary Hospital of the Second Military Medical University
Shanghai, Shanghai Municipality, China
Department of Gastroenterology, General Hospital of Western Theater Command
Chengdu, Sichuan, China
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang J, Rossle M, Zhou X, Deng J, Liu L, Qi X. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Curr Med Res Opin. 2019 May;35(5):859-868. doi: 10.1080/03007995.2018.1552575. Epub 2019 Jan 4.
Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, Han D, Liu F, Qi X. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Nov;97(48):e13437. doi: 10.1097/MD.0000000000013437.
Zhou XM, Qi XS, Jia JD. [An evidence-based terlipressin therapy for gastroesophageal variceal hemorrhage]. Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):245-248. doi: 10.3760/cma.j.issn.1007-3418.2018.04.002. Chinese.
Xu X, Liu B, Lin S, Li B, Wu Y, Li Y, Zhu Q, Yang Y, Tang S, Meng F, Chen Y, Yuan S, Shao L, Bernardi M, Yoshida EM, Qi X. Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study. Adv Ther. 2020 Oct;37(10):4396-4413. doi: 10.1007/s12325-020-01466-z. Epub 2020 Aug 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XHNKKY-VASO 2.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.